

April 27, 2009
AnGes MG, Inc.

Joint R&D with Morishita Jintan Co., Ltd.

-Development of New Products Based on Functional Peptides with Antimicrobial Activity-

AnGes MG, Inc. announces that it has entered into a basic agreement with Morishita Jintan Co., Ltd. (Morishita Jintan) concerning cooperative research and development with the aim of developing new products based on functional peptides with antimicrobial activity.

Functional peptides with antimicrobial activity were discovered during a research project conducted by AnGes MG's group. AnGes MG has been exploring ways of applying these peptides and has recently reached an agreement with Morishita Jintan over joint R&D with the aim of developing new products making use of these peptides.

AnGes MG has filed an application for patent registration for this joint R&D project's functional peptides with antimicrobial activity, and possesses data endorsing their effectiveness. Morishita Jintan has been playing a significant role in the field of medical care products such as medical devices and quasi-medicines (e.g., wound protective materials). Products making use of these peptides will be developed while fully utilizing the resources of both companies.

This project will have negligible effect on AnGes MG's performance during the current fiscal year and there will be no revision to the forecast.

- Company Profile -

Company name :	Morishita Jintan Co., Ltd.
Headquarters :	1-2-40 Tamatsukuri, Chuo-ku, Osaka
Representative :	Junichi Komamura, Representative Director & President
Established :	November 1936
Capital :	3,537 million yen (September 30, 2008)
Number of employees :	217 (September 30, 2008)
Consolidated net sales :	7,387 million yen (term ending March 2008)
Scope of business :	Manufacture and distribution of medicines, quasi-medicines, medical devices, food, etc.